Daniel Jaeck

TL;DR: In this article, the authors compared the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.

TL;DR: Five‐year survival rates after resection of liver metastases from colorectal carcinoma are close to 25%, and selection of patients likely to benefit from surgery remains controversial and subjective.

TL;DR: Overall survival data after long-term follow-up found no difference in overall survival with the addition of perioperative chemotherapy with FOLFOX4 compared with surgery alone for patients with resectable liver metastases from colorectal cancer, however, the previously observed benefit in PFS means it should remain the reference treatment for this population of patients.

TL;DR: One of the most important findings in the evolution of LT is the considerable improvement of results along time with, for the mean time, a one‐year survival of 83%, all indications confounded.

TL;DR: This procedure may be able to overcome the shortcomings of “conventional” two-stage hepatectomy and result in an increased number of patients who could benefit from surgical treatment despite initially unresectable hepatic malignancies due to too small future liver remnant volume.